Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate-Reference-Cited by-同舟云学术

Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate

Published:1999-01 Issue:1 Volume:24 Page:65-68
ISSN:8756-3282
Container-title:Bone
language:en
Short-container-title:Bone

Author:

Watts N.B,Becker P

Publisher

Elsevier BV

Subject

Histology,Physiology,Endocrinology, Diabetes and Metabolism

Reference11 articles.

1. Bone turnover in postmenopausal osteoporosis;Civitelli;J Clin Invest,1988

2. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis;Devogelaer;Bone,1996

3. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis;Harris;Am J Med,1993

4. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis;Liberman;N Engl J Med,1995

5. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss;Marslew;Obstet Gynecol,1992

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bone Mass Outcomes in Patients With Osteoporosis Treated With Risedronate After Alendronate Failure: a 12-Month Follow-Up Study;Journal of Clinical Densitometry;2017-01

2. Bisphosphonates Induce Senescence in Normal Human Oral Keratinocytes;Journal of Dental Research;2011-03-22

3. Systematic Review and Meta-analysis of Real-World Adherence to Drug Therapy for Osteoporosis;Mayo Clinic Proceedings;2007-12-01

4. Systematic Review and Meta-analysis of Real-World Adherence to Drug Therapy for Osteoporosis;Mayo Clinic Proceedings;2007-12

5. Analytical and preanalytical issues in measurement of biochemical bone markers;LAB MED;2005